Arcturus raises $50M from Meiji at 80% premium to fund mRNA pipeline
What's the deal? Arcturus Therapeutics has secured a $50 million equity investment from Japan's Meiji Seika PharmaDealroom has a profile for this one. Try Dealroom → as part of an expanded collaboration. MeijiDealroom has a profile for this one. Try Dealroom → will buy unregistered shares at $20.27 each — an 80% premium — leaving it with 7.9% of the San Diego messenger RNA medicines company.
What's the endgame? Arcturus will use the proceeds to accelerate ARCT-2601, its treatment for ornithine transcarbamylase (OTC) deficiency and the first therapeutic to use its next-generation LUNAR 2.0 delivery platform. The funds also support the company's cystic fibrosis program.
What else is in the deal? Beyond the cash, the two signed an exclusive license covering Arcturus' ARCT-154 technology for an undisclosed therapeutic area. They also agreed a memorandum of understanding on pandemic preparedness and response in Japan.
The investment "reflects Meiji's confidence in our development capabilities and the potential of our technology platform," said Joseph Payne, president and chief executive officer of Arcturus.
Why now? Meiji already distributes KOSTAIVE, Arcturus' self-amplifying mRNA COVID-19 vaccine, in Japan. The deal deepens that relationship after Arcturus and CSL Seqirus ended their broader vaccine collaboration in August 2026, returning control of the vaccine portfolio to Arcturus.
What could go wrong? Arcturus' pipeline remains early. ARCT-2601 Phase 2 dosing is planned for the first quarter of 2027, with top-line data in the second half of the year — so clinical outcomes are still unproven.
The signal: The round stands out in a sector where vaccine developers have struggled to attract venture funding. For Arcturus, a strategic backer paying a premium offers both capital and a clearer path to commercialising vaccines in Japan.
Read more: business.thepilotnews.com
Image credit: Generated with Gemini